Singh Devendra Pratap, Borse Swapnil P, Nivsarkar Manish
Department of Pharmacology and Toxicology, B.V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad, Gujarat 380054, India; Registered Ph.D Scholar (External) at Institute of Pharmacy, NIRMA University, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat 382481, India.
Department of Pharmacology and Toxicology, B.V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad, Gujarat 380054, India.
Exp Toxicol Pathol. 2017 Jan;69(1):17-26. doi: 10.1016/j.etp.2016.10.004. Epub 2016 Oct 22.
Management of Nonsteroidal anti-inflammatory drug (NSAID)-induced gastroenteropathy has emerged as a major medical and socioeconomic problem mainly because the highly efficacious gastroprotective drugs i.e. proton pump inhibitors (PPIs) like pantoprazole sodium (PTZ), worsen the NSAID-induced enteropathic damage and lack of approved therapeutic strategies/interventions to prevent this damage. Hence, the primary objective of the current study was to assess whether we can protect the GI mucosa against gastroenteropathic damage caused by diclofenac sodium (DIC) in rats by co-administration of PTZ and quercetin (QCT). Rats were treated twice daily with QCT (35, 50 and 100mgkg peroral) and/or PTZ (4mgkg) or vehicle for a total of 10 days. In some experiments, DIC (9mgkg) was administered orally twice daily for the final 5days of PTZ/QCT+PTZ/vehicle administration. Rats in all the groups were fasted after the last dose on 9th day, but, water was provided ad libitum. 12h after the last dose on 10th day, rats were euthanized and their GI tracts were assessed for haemorrhagic damage, lipid peroxidation, intestinal permeability and GI luminal pH alterations along with haematological and biochemical estimations. The experimental evidences suggested that co-administration of QCT with PTZ significantly attenuated the exacerbation of NSAID-induced enteropathic damage in a dose dependent manner. The combination of PTZ 4mgkg and QCT at the doses of 50 or 100mgkg was found to effective in preventing the DIC-induced gastroenteropathy. The present report focuses on the gastroenteroprotective ability of QCT and the mechanisms may be related to its ability to prevent GI blood loss, the lipid peroxidation, intestinal permeability alteration and alteration in GI luminal pH.
非甾体抗炎药(NSAID)所致胃肠病的管理已成为一个主要的医学和社会经济问题,主要原因是高效的胃保护药物,即质子泵抑制剂(PPI),如泮托拉唑钠(PTZ),会加重NSAID所致的肠病损伤,且缺乏批准的治疗策略/干预措施来预防这种损伤。因此,本研究的主要目的是评估通过联合给予PTZ和槲皮素(QCT),是否能保护大鼠胃肠道黏膜免受双氯芬酸钠(DIC)所致的胃肠病损伤。大鼠每天口服两次QCT(35、50和100mg/kg)和/或PTZ(4mg/kg)或赋形剂,共10天。在一些实验中,在PTZ/QCT+PTZ/赋形剂给药的最后5天,每天口服两次DIC(9mg/kg)。第9天最后一次给药后,所有组的大鼠禁食,但可自由饮水。第10天最后一次给药12小时后,对大鼠实施安乐死,并评估其胃肠道的出血损伤、脂质过氧化、肠道通透性和胃肠道管腔pH值变化,同时进行血液学和生化评估。实验证据表明,QCT与PTZ联合给药以剂量依赖的方式显著减轻了NSAID所致肠病损伤的加重。发现4mg/kg的PTZ与50或100mg/kg剂量的QCT联合使用可有效预防DIC所致的胃肠病。本报告重点关注QCT的胃肠保护能力,其机制可能与其预防胃肠道失血、脂质过氧化、肠道通透性改变和胃肠道管腔pH值改变的能力有关。